Ernexa Therapeutics Advances ERNA-101 Development, Plans IND Submission in 2026
Ernexa Therapeutics announced progress in the development of ERNA-101, the company's therapeutic candidate, achieving multiple milestones that position the program for a planned investigational new drug submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study. The company has successfully completed process development activities for the ERNA-101 manufacturing process and has now transitioned into Good Manufacturing Practice, or GMP, manufacturing in preparation for clinical development. In parallel, technology transfer activities for ERNA-101 are actively underway, representing another major operational milestone supporting the planned IND submission timeline. IND submission for ERNA-101 targeted for Q3.
